Cleveland Clinic, Cleveland, Ohio, USA.
University of Florida, Gainesville, Florida, USA.
Mov Disord. 2015 Nov;30(13):1825-30. doi: 10.1002/mds.26429.
Fatigue affects 40% to 50% of all PD patients and is a leading cause of disability, with no clearly established or efficacious established treatments.
In this double-blinded, placebo-controlled, pilot trial, we investigated whether rasagiline improved fatigue among PD patients. Subjects were randomized to 1 mg daily of rasagiline or placebo for 12 weeks. The primary endpoint was a change in the Modified Fatigue Impact Scale from baseline to week 12.
Thirty PD subjects (16 men), with Modified Fatigue Impact Scale baseline score of 67 ± 15, were randomized (16 to rasagiline vs. 14 to placebo). Significant improvement was noted in the mean Modified Fatigue Impact Scale score of the rasagiline group (12 points) as compared to placebo (8.5 points) from baseline to week 12 (P = 0.003).
In this pilot study, rasagiline at a dose of 1 mg per day improved fatigue. Larger randomized studies are needed to confirm this finding.
疲劳影响所有 PD 患者的 40%至 50%，是导致残疾的主要原因，但目前尚无明确有效的治疗方法。
在这项双盲、安慰剂对照的初步试验中，我们研究了雷沙吉兰是否能改善 PD 患者的疲劳。受试者随机分为每天 1 毫克雷沙吉兰或安慰剂治疗 12 周。主要终点是从基线到第 12 周时改良疲劳影响量表的变化。
30 名 PD 患者（16 名男性），改良疲劳影响量表基线评分为 67 ± 15，随机分为雷沙吉兰组（16 名）和安慰剂组（14 名）。与安慰剂组（8.5 分）相比，雷沙吉兰组的平均改良疲劳影响量表评分从基线到第 12 周显著改善（12 分）（P = 0.003）。
在这项初步研究中，每天 1 毫克的雷沙吉兰可改善疲劳。需要更大规模的随机研究来证实这一发现。
